Investor Alert: Legal Investigation into NeoGenomics, Inc.
The legal firm Pomerantz LLP has announced an investigation into NeoGenomics, Inc. (NASDAQ: NEO) on behalf of its shareholders. Investors are encouraged to reach out to Danielle Peyton at [email protected] or call 646-581-9980, ext. 7980, for more information.
Focus of the Inquiry
The inquiry focuses on whether NeoGenomics and some of its executives or directors may have engaged in securities fraud or other illegal business activities.
Financial Disclosures and Market Reaction
On July 29, 2025, NeoGenomics disclosed its financial results for the second quarter, revealing revenue of $181.3 million—below analysts' expectations—and a net loss of $45.1 million. The company also downgraded its 2025 revenue outlook to between $720 million and $726 million, down from approximately $753 million. Additionally, the adjusted EBITDA forecast was reduced to a range of $41 million to $44 million from prior estimates of $55 million to $58 million.
Following this announcement, NeoGenomics' stock price dropped by $1.21, or 18.73%, closing at $5.25 per share on July 29, 2025.